Pharmacogenetics of cytotoxic drugs

A K Daly1, A G Hall

  • 1Department of Pharmacological Sciences, University of Newcastle Medical School, Framlington Place, Newcastle-upon-Tyne, NE2 4HH, UK.

Insights

This review covers genetic variations impacting cytotoxic drug processing and transport. Future pharmacogenetics research will integrate advanced technologies like microarray analysis for personalized cancer treatment.

Area of Science:

  • Pharmacogenetics
  • Molecular Biology
  • Oncology

Background:

  • Cytotoxic drugs are crucial in cancer therapy but exhibit variable efficacy and toxicity.
  • Individual genetic differences significantly influence drug metabolism and transport.
  • Understanding these genetic factors is key to optimizing treatment outcomes.

Purpose of the Study:

  • To review key genetic polymorphisms affecting cytotoxic drug pharmacokinetics.
  • To explore emerging technologies and future directions in pharmacogenetics.
  • To highlight the role of genetic profiling in personalized cancer medicine.

Main Methods:

  • Literature review of genetic polymorphisms in drug-metabolizing enzymes and transporters.
  • Discussion of current and emerging pharmacogenetic technologies.
  • Analysis of microarray-based tumor classification methods.

Main Results:

  • Identified major genetic polymorphisms influencing the efficacy and toxicity of cytotoxic agents.
  • Highlighted the potential of pharmacogenetics to predict drug response.
  • Discussed the integration of genomic data for improved patient stratification.

Conclusions:

  • Genetic polymorphisms are critical determinants of cytotoxic drug response.
  • Pharmacogenetics offers a pathway to tailor cancer therapies for individual patients.
  • Emerging technologies like microarray analysis will advance personalized oncology.

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...